Search results
Author(s):
AA Kroon
,
PW de Leeuw
Added:
3 years ago
Hypertension is a common and serious problem that is the major cause of morbidity and mortality worldwide.1–3 Over 70 million people in the US are affected by high blood pressure (BP) that requires treatment, and nearly one-third of the adult population in the US have a BP of ≥140/90mmHg, which is the defined cut-off value for hypertension.2,4 It is estimated that over 44% of people in Europe are…
View more
Author(s):
Michel Burnier
Added:
3 years ago
In 2007, the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) published their guidelines for the management of arterial hypertension.1 These guidelines covered in detail all aspects of the management of hypertensive patients, from the diagnosis and detection of early subclinical organ damage to the discussion of the various therapeutic strategies in essential…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Stay updated on the AHA 22 late-breaking data!
In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions.
What are the key take-aways from AHA 22? What are the most promising findings? How should we understand…
View more
Author(s):
M Rizzo
,
I Colomer-Asenjo
,
M Sutil-Vega
,
et al
Added:
3 years ago
Aims: To assess the clinical and neurohormonal characteristics of patients eligible to sacubitril/valsartan (SV) attending to an outpatient heart failure clinic and describe variables related to SV prescription in real-life heart failure patients.
Design and methods: We collected data from 119 consecutive patients attending our heart failure outpatient clinic between May 2018 and November 2018.
…
View more
Author(s):
Ferenc Follath
Added:
3 years ago
Q: What are the new treatment options in acute decompensated heart failure?
A: The new treatment options are the two recently introduced drugs, the calcium sensitiser, levosimendan which has been introduced in many European countries, and a B-type natriuretic peptide (BNP) Analogon nesiritide, utilised primarily in the US. This BNP causes basal dilation and improves diuresis.
Q: How do these…
View more
Thomas Kahan
Research Area(s) / Expertise:
Author
Cardio-oncology A-Z
Video Series
Author(s):
Adrian JB Brady
Added:
3 years ago
Hypertension is the single most important preventable cause of premature death in the Western world. The quest to find the most effective treatment both in terms of blood pressure control and prevention of events, such as heart attacks and strokes, is on-going. The issue of which antihypertensive agent to use first-line has been the subject of debate for over two decades. The lack of a coherent…
View more
David Goldsmith
Author
Atul Pathak
Job title: Professor
Author